Cassava Sciences (SAVAW) Stock Analysis

What Cassava Sciences does

Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation. Furthermore, the company is advancing SavaDx, a diagnostic tool utilizing blood-based biomarkers for the early detection of Alzheimer's disease. Incorporated in 1998, the organization was previously known as Pain Therapeutics, Inc. until its name change to Cassava Sciences, Inc. in March 2019. The company's headquarters are located in Austin, Texas.

Key metrics

ETFs linked to SAVAW

Broad-market and Healthcare sector ETFs an investor holding Cassava Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SAVAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cassava Sciences?

Cassava Sciences trades under the ticker SAVAW on NASDAQ.

Which exchange is SAVAW listed on?

SAVAW is listed on NASDAQ.

What sector does Cassava Sciences operate in?

Cassava Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SAVAW in a portfolio?

PortView shows SAVAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.